-
公开(公告)号：US09556139B2
公开(公告)日：2017-01-31
申请号：US14702947
申请日：2015-05-04
申请人： Array BioPharma Inc.
发明人： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff , Ganghyeok Kim
IPC分类号： A61K31/352 , C07D311/58 , C07D405/12 , C07D407/12
CPC分类号： C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
摘要： Provided herein are compounds of Formula I: in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, which are DP2 receptor modulators useful in the treatment of immunologic diseases.
摘要翻译： 式（Ⅳ，Ⅵ）化合物：其中A1，A2，P2，P3，R7a，R7b，R8，R9，R10和Z2具有说明书中给出的含义，是可用于制备DP2受体调节剂的化合物 免疫疾病的治疗。
-
公开(公告)号：US20160304519A1
公开(公告)日：2016-10-20
申请号：US15197445
申请日：2016-06-29
发明人： James F. Blake , Adam Cook , John Gaudino , Indrani W. Gunawardana , Erik James Hicken , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Jacob Schwarz , Huifen Chen , Lewis Gazzard , Jane Schmidt , Steve Do
IPC分类号： C07D471/04 , A61K31/5377 , A61K31/55 , A61K31/444 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/506
CPC分类号： C07D471/04 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D487/04 , C07D519/00
摘要： Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
摘要翻译： 提供式I化合物或其立体异构体，互变异构体或其药学上可接受的盐，其可用于治疗疾病。 公开了使用式I化合物或其立体异构体，互变异构体或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗这些疾病或相关病理状况的方法。
-
公开(公告)号：US09096567B2
公开(公告)日：2015-08-04
申请号：US14231356
申请日：2014-03-31
申请人： Array BioPharma Inc.
发明人： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff , Ganghyeok Kim
IPC分类号： A61K31/352 , C07D311/04 , C07D311/58 , C07D405/12 , C07D407/12
CPC分类号： C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
摘要： Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 are as defined herein.
摘要翻译： 本文提供了一种治疗哺乳动物中选自哮喘，皮炎，过敏性鼻炎，荨麻疹，过敏反应，血管紧张素，过敏，接触超敏反应，药物过敏和过敏性结膜炎的过敏性炎性疾病的方法，其包括给予治疗有效量的化合物 其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10如本文所定义。
-
公开(公告)号：US20140221342A1
公开(公告)日：2014-08-07
申请号：US14231356
申请日：2014-03-31
申请人： Array BioPharma Inc.
发明人： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff , Ganghyeok Kim
IPC分类号： C07D311/58 , C07D407/12 , C07D405/12
CPC分类号： C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
摘要： Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 are as defined herein.
摘要翻译： 本文提供了一种治疗哺乳动物中选自哮喘，皮炎，过敏性鼻炎，荨麻疹，过敏反应，血管紧张素，过敏，接触超敏反应，药物过敏和过敏性结膜炎的过敏性炎性疾病的方法，包括给予治疗有效量的化合物 其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10如本文所定义。
-
公开(公告)号：US10766881B2
公开(公告)日：2020-09-08
申请号：US16276326
申请日：2019-02-14
申请人： Array BioPharma Inc.
发明人： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC分类号： C07D403/14 , C07D413/14 , C07D401/14 , G01N33/574 , A61K31/501 , A61K45/06 , A61K31/5377 , C12Q1/6886
摘要： Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号：US10208024B2
公开(公告)日：2019-02-19
申请号：US15333148
申请日：2016-10-24
发明人： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC分类号： C07D403/14 , C07D401/14 , C07D413/14 , A61K31/501 , A61K31/5377 , C12Q1/68 , A61K45/06 , C12Q1/6886 , G01N33/574
摘要： Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号：US20160303126A1
公开(公告)日：2016-10-20
申请号：US15197479
申请日：2016-06-29
发明人： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC分类号： A61K31/506 , C07D403/14 , C07D471/04 , A61K31/4439 , C07D417/14 , C07D403/04 , C07D401/14 , A61K31/444 , A61K45/06 , C07D405/14
CPC分类号： A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
摘要： Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US20170348310A1
公开(公告)日：2017-12-07
申请号：US15684733
申请日：2017-08-23
发明人： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC分类号： A61K31/506 , C07D417/14 , C07D405/14 , C07D403/04 , A61K31/4439 , C07D401/14 , A61K45/06 , A61K31/444 , C07D471/04 , C07D403/14
CPC分类号： A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
摘要： Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
9.发明申请公开(公告)号：US20170260168A1
公开(公告)日：2017-09-14
申请号：US15333148
申请日：2016-10-24
发明人： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC分类号： C07D403/14 , A61K31/501 , G01N33/574 , A61K31/5377 , C07D401/14 , C12Q1/68 , A61K45/06 , C07D413/14
CPC分类号： C07D403/14 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D413/14 , C12Q1/6886 , G01N33/574
摘要： Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号：US09670208B2
公开(公告)日：2017-06-06
申请号：US15197445
申请日：2016-06-29
发明人： James F. Blake , Adam Cook , John Gaudino , Indrani W. Gunawardana , Erik James Hicken , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Jacob Schwarz , Huifen Chen , Lewis Gazzard , Jane Schmidt , Steve Do
IPC分类号： C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/506 , A61K31/444 , C07D487/04 , C07D519/00 , A61K31/55
CPC分类号： C07D471/04 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D487/04 , C07D519/00
摘要： Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.028 秒)
